Munich-based medtech
company Noxon has closed its seed funding round, led by High-Tech Gründerfonds
(HTGF) and Bayern Kapital, with participation from Auxxo and another
institutional investor. The size of the round was not disclosed.
In rehabilitation and the
treatment of neuromuscular disorders, muscle diagnostics and activation are
typically performed intermittently in clinical settings. As a result, patients
often lack continuous data and adaptive therapy in their daily lives throughout
the treatment process.
Noxon aims to address this
gap with a medical Muscle-Computer Interface that combines continuous muscle
diagnostics and neuromuscular electrical stimulation (NMES) in a wearable
designed for everyday use.
The core innovation is a closed feedback loop that
enables real-time measurement and personalised muscle and nerve activation
throughout therapy, integrated into existing formats such as tapes, patches,
and orthopaedic aids.
Noxon is also working with
medical partners, including University Hospital Würzburg and the neuroscience
group N-Squared Lab, on additional pilot applications. The collaboration
focuses on supporting muscle control when signal transmission between the brain
and muscle is impaired, including approaches aimed at reducing tremor in
Parkinson’s patients.
With the new funding, Nexon will advance clinical validation of its platform and support the launch of its initial products, aiming to make muscle health more transparent, personalised, and accessible.